Transforming The Biopharmaceutical Industry: Addressing Patient Access To Medicines With Interconnected Networks

By Francisco Gonzalez, Associate Director of Strategic Technical Marketing, and Lisa Emily, Director of Corporate Communications

The biopharmaceutical industry is thriving, despite challenges brought on by the pandemic. The market is expected to reach $800 billion by 2030. To meet customer needs, CDMOs are focusing on providing capacity, reducing complexity, and offering scientific expertise.

Customers seek CDMO partners who can support the entire product lifecycle, from pre-clinical to commercial manufacturing. They value experience, quality, and regulatory compliance.

FUJIFILM Diosynth Biotechnologies (FDB) is a CDMO that emphasizes trust and a holistic approach. Their Partners for Life strategy and KojoX operational philosophy aim to transform the industry by improving efficiency and flexibility. KojoX utilizes modular design to create a uniform operating system across facilities. This allows for faster tech transfers, adaptable manufacturing, and quicker time-to-market.

In this article, learn more about FDB's scientific expertise and experience in various drug substances and products.